The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
The kit preserves viral nucleic acids in a non-hazardous stabilization solution that inactivates common respiratory viruses for safer sample collection
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
The NanoDrop Eight simultaneously evaluates eight samples in 20 seconds or less and the instrument can also measure high-concentration samples of up to 200 absorbance units without dilution
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Barbara Engelhardt moves her computational and statistics lab to Gladstone
The order strengthens the company’s position in the East African market
Subscribe To Our Newsletter & Stay Updated
